Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vumerity

EU flag

Antibiotics among 7 new drugs backed by EMA

The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval

- PMLiVE

CHMP thumbs up for Novo’s obesity drug Saxenda

Diabetes drug liraglutide on course for new indication in EU

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

- PMLiVE

‘Major step forward’ as EMA recommends first stem cell therapy

But wants more clinical trial data to shore up orphan drug's marketing licence

- PMLiVE

Novartis’ Gilenya fails in difficult-to-treat form of MS

Drug no better than placebo as a treatment for primary progressive multiple sclerosis

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

FDA adds rare brain infection link to Tecfidera labelling

Biogen Idec’s MS drug gets safety warning

- PMLiVE

Merck Serono brings electronic MS device to six more countries

RebiSmart works alongside the company's MSdialog web-based software

Sanofi reception

Sanofi persuades FDA to back its MS drug Lemtrada

But only for a limited patient population, with boxed warnings and a risk plan

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

Biogen Idec launches online multiple sclerosis programme

MS Blueprint aims to help people with MS develop a personalised support plan

National Institute for Health and Care Excellence NICE logo

NICE denies two drugs in new MS guidance

Sativex and Fampyra too costly for NHS in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links